Render Target: STATIC
Render Timestamp: 2024-10-04T10:23:26.045Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Cilostazol #33528

    Product Information

    Product Usage Information

    Cilostazol is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 0.90 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 369.5 g/mol
    Purity >98%
    Molecular Formula C20H27N5O2
    CAS 73963-72-1
    Solubility Soluble in DMSO at 20 mg/mL.

    Background

    Cilostazol is a potent inhibitor (IC50 = 0.57 μM) of phosphodiesterase 3 (PDE3) and also inhibits the uptake of adenosine into muscle, endothelial cells, erythrocytes, and platelets (1). PDE3 hydrolyses both cAMP and cGMP, and plays a role in regulating cAMP-mediated signaling in a number of cell and tissue types, but is particularly important in regulating heart muscle, vascular smooth muscle, and platelet aggregation (2). Clinical studies demonstrate that Cilostazol is effective against inflammation, insulin resistance, and cardiomyopathy. Cilostazol, in conjunction with anti-platelet medication, reduced risk of restenosis, amputation, and target lesion revascularization following peripheral vascular interventions (3). Treatment of a murine model of obesity-associated left ventricular diastolic dysfunction with Cilostazol and hypertension medication resulted in improved left ventricular function and reduced TGF-β1/SMAD3 and Akt/mTOR signaling (4). Cilostazol is seen as more effective than aspirin in preventing recurrent ischemic stroke and intracranial hemorrhage (5), and as a potential treatment of Raynaud syndrome (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.